Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Combination product jurisdiction

This article was originally published in The Gray Sheet

Executive Summary

FDA's 1991 Intercenter Agreements "should not be independently relied upon," although they "may still be helpful in certain situations," OCP advises in a FDL-1jurisdictional update posted on its website Sept. 6. The ICAs provided some guidance for how combination products would be regulated based on the "way the world was in 1991," OCP Director Mark Kramer said, but his office is working to create processes that are "more translatable to the future." OCP recently issued guidance on writing a request for center designation, incorporating the agency's primary mode of action 1final rule. It also posted two concept papers Sept. 6...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT022634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel